VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) announces that further to its news releases of July 15 and July 23, 2025, the Company has closed non-brokered private placements of Units (the “Offerings”) for total gross proceeds of C$2,450,000 with Eric Sprott as lead investor. Pursuant to the closing of the Offerings, the Company has issued 5,681,818 Units at $0.22 comprising 5,618,818 common shares ...

Core Viewpoint - Smart Share Global Limited has announced a definitive Merger Agreement with Mobile Charging Group Holdings Limited, implying an equity value of approximately US$327 million for the company [1][3]. Merger Details - The Merger will result in each American Depository Share (ADS) being exchanged for US$1.25 in cash, while each Class A Share will be exchanged for US$0.625 in cash [2]. - The Merger Consideration represents a premium of 74.8% to the closing trading price of the ADSs on January 3, 2025, and a premium of approximately 8.7% to the closing price on July 31, 2025 [3]. Consortium Composition - The Consortium acquiring Smart Share includes Trustar Mobile Charging Holdings Limited and key executives from the company, including the Chairman and CEO, Mars Guangyuan Cai [4]. Funding Structure - The Merger will be funded through cash contributions from Consortium members, a committed term loan facility from Bank of China Limited, and rollover equity contributions from Rollover Shareholders [5]. Board Approval - The Merger Agreement has been approved by the Board, following a unanimous recommendation from a Special Committee of independent directors [6]. Closing Conditions - The Merger is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including shareholder approval and regulatory approvals [7]. Company Background - Smart Share Global Limited, also known as Energy Monster, is a leading provider of mobile device charging services in China, with 9.6 million power banks across over 1.2 million points of interest [15].

Core Points - Lakeland Industries, Inc. declared a cash dividend of $0.03 per share for its fiscal third quarter of 2026, payable on August 22, 2025, to stockholders of record as of August 15, 2025 [1] Company Overview - Lakeland Fire + Safety is a global manufacturer of protective clothing and apparel for various sectors including industry, healthcare, and first responders [2] - The company sells a comprehensive line of fire services and industrial protective clothing and accessories through in-house sales teams and authorized independent sales representatives [2] - Lakeland's products are distributed globally, serving industries such as oil, chemical, automobile, transportation, and healthcare, among others [2] - The company has a diverse international market presence, selling to over 50 countries, with significant sales in China, the EEC, Canada, and several Latin American countries [2]

Core Points - NuCana plc will change the ratio of its American Depository Shares (ADSs) from one ADS representing twenty-five ordinary shares to one ADS representing five thousand ordinary shares, effective August 11, 2025 [1][2] - This change is equivalent to a one-for-two hundred reverse ADS split and aims to support liquidity and regain compliance with Nasdaq's minimum bid price requirement [2][3] - The exchange will occur automatically for holders of uncertificated ADSs, while certificated holders must surrender their ADSs for cancellation [2] - The change will not affect shareholders' proportional equity interests, except for fractional ADSs, which will be aggregated and sold [2] - The trading price of ADSs is expected to increase proportionally, although no assurance can be given regarding the actual trading price post-change [3] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology [4] - The company is developing new medicines, ProTides, to enhance the efficacy and safety of conventional chemotherapy agents [4] - NuCana's pipeline includes NUC-7738, currently in Phase 2 studies for advanced solid tumors, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [4]

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 07/31/2025 136,975,159 Total gross of voting rights: 136,975,159 Total net* of voting rights: 136,810,568 * Net total = total number of voting rights attached to shares – shares wi ...

Core Viewpoint - Nanox Imaging Ltd is set to report its financial results for Q2 2025 on August 12, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss these results and provide a business update [1]. Company Overview - Nanox is focused on advancing preventive healthcare through affordable medical imaging technologies that utilize advanced AI and proprietary digital X-ray sources [3]. - The company's vision includes expanding its technology's reach beyond hospital settings, offering a comprehensive solution from scanning to diagnosis, and leveraging AI for improved diagnostic accuracy [4]. Product and Service Ecosystem - Nanox.ARC: A multi-source digital tomosynthesis system that is cost-effective and user-friendly [4]. - Nanox.AI LTD: A subsidiary that provides AI-based algorithms to enhance routine CT imaging readings, focusing on early signs of chronic diseases [4]. - Nanox.CLOUD: A cloud-based platform for managing data from Nanox devices, offering tools for detailed imaging analysis [4]. - Nanox.MARKETPLACE: A decentralized marketplace through USARAD Holdings Inc. that provides remote access to radiology and cardiology experts, along with a teleradiology services platform [4].

Company Announcement - Rumble Inc. will release its financial results for the fiscal quarter ended June 30, 2025, before market open on August 11, 2025 [1] - A conference call will be hosted on the same day at 11:30 a.m. Eastern Time [1] Investor Relations - Access to the live webcast and replay of the conference call, along with related earnings release materials, will be available on Rumble's Investor Relations website [2] Company Overview - Rumble is a high-growth video platform and cloud services provider focused on creating an independent infrastructure [3] - The company's mission is to restore the internet to its roots by making it free and open again [3]

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive ...

Core Viewpoint - Tevogen Bio Holdings Inc. is transitioning from a biotechnology innovator to a dynamic enterprise that integrates artificial intelligence into its operations, aiming to deliver impactful and affordable therapies through advanced science and technology [1][2]. Group 1: Company Developments - Tevogen has validated its proprietary ExacTcell™ platform and completed a successful proof-of-concept clinical trial for its first product, while also establishing a drug discovery R&D center and working on a GMP cell manufacturing facility [2]. - The company has launched its AI-driven PredicTcell™ platform, enhancing target discovery efficiency and forming strategic partnerships with technology leaders like Microsoft and Databricks [3]. - Tevogen has a robust intellectual property portfolio, with recent patent filings that secure its position in AI-driven predictive modeling [3]. Group 2: Financial Position and Growth Strategy - Tevogen is well-capitalized and has access to necessary funding to execute its growth strategy, including the development of Tevogen.AI [4]. - The company highlights a 74% insider equity ownership, reinforcing its long-term vision and commitment to its mission [2][7]. - The establishment of a new in-house cell therapy manufacturing facility is underway, which is expected to enhance operational capabilities [7]. Group 3: Innovation and Cost Efficiency - The collaboration with Microsoft and Databricks has led to a drastic reduction in target analysis time, potentially saving billions in drug development costs [7]. - The new headquarters, funded by the CEO, centralizes R&D and AI teams to accelerate innovation within the company [7].

Banco Comercial Português, S.A. informs about 2025 EU-Wide Stress Test Results Attachment 2025 08 01 Stress Tests_EN ...